INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

	Approved for use through 07/31/2012.
Application Number	10/556,069
Confirmation Number	6079
Filing Date	August 24, 2006
First Named Inventor	Peter MAYRHOFER
Art Unit	1633
Examiner Name	Sumesh KAUSHAL
Attorney Docket Number	Q90909

U.S. PATENTS								
Examiner Initials*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		

	U.S. PATENT APPLICATION PUBLICATIONS							
Examiner Initials* Cite No Publication Number Kind Code¹ Publication Date Name of Patentee or Applicant of cited Document Relevant Figures Appear								

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	1.	02/20823	wo	A2	2002-03-14	THE SALK INSTITUTE FOR BIOLOGICAL STUDIES		

		NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, calalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.				
	2.	Notice of Opposition filed in corresponding EP Patent Application No. 04730974.5 (Patent No. 1620559) on March 24, 2010.			
	3.	Jan A. GOSSEN et al, "Plasmid Rescue from Transgenic Mouse DNA Using LacI Repressor Protein Conjugated to Magnetic Beads", BioTechniques, 1993, 14(4): 624-629.			
	4.	Noaman HASAN et al., "Construction of <i>lacits</i> and <i>Lacits</i> expression plasmids and evaluation of the thermosensitive <i>lac</i> repressor", Gene, 1995, 163: 35-40.			
	5.	Extended European Search Report issued in corresponding EP Patent Application No. 10157309.5 on June 8, 2010 (in the name of Austria Wirtschaftsservice Gesellschaft mbH).			
	6.	Joakim LUNDEBERG et al., "Affinity Purification of Specific DNA Fragnments Using a <i>lac</i> Repressor Fusion Protein", Genet. Anal. Techn. Appl., 1990, 7:47-52.			
	7.	Steven W. GRANGER et al., "Purification of Moloney Murine Leukemia Virus Chromatin from Infected Cells by an Affinity Method", J. Biomed. Sci., 2001, 8: 278-289.			
	8.	John R. SADLER et al., "Plasmids Containing Many Tandem Copies of a Synthetic Lactose Operator", Gene, 1980, 8: 279-300.			
	9.	A-M DARQUET et al., "Minicircle: an improved DNA molecule for <i>in vitro</i> and <i>in vivo</i> gene transfer", Gene Therapy, 1998, 6: 209-218.			
	10.	Third Party Observations filed in corresponding EP Patent Application No. 10157309.5 on May 31, 2011 (in the name of Austria Wirtschaftsservice GmbH).			
	11.	Peter J. SCHATZ, "Use of Peptide Libraries to Map the Substrate Specificity of a Peptide-Modifying Enzyme: A 13 Residue Consensus Peptide Specifies Biotinylation of Escherichia coli", Bio/Technology, 1993, 11: 1183-1143.			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patient Documents at www.USPTO.GOV or MPEP.901.04. 2. Enter office that issued the document, by the two-fetter code (WIPO Standard ST3.) 3. For Japanese patient documents, the indication of the year of the region of the Empirer may precede the sealing number of the patient document. 4 Kind of document when the patient document will be patient to the patient to the patient document will be patient to the pat

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

	Approved for use through 07/31/2012.
Application Number	10/556,069
Confirmation Number	6079
Filing Date	August 24, 2006
First Named Inventor	Peter MAYRHOFER
Art Unit	1633
Examiner Name	Sumesh KAUSHAL
Attorney Docket Number	090909

	NON-PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	T ⁶					
	12.	John R. SADLER et al., "A Perfectly Symmetric lac Operator Binds the lac Repressor Very Tightly", Proceedings of the National Academy of Science of the USA. 1983, 80: 6785-6789.						

EXAMINER SIGNATURE							
Examiner Signature		Date Considered					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patient Documents at www.USPTO.GOV or MPEP.901.04. 2 Enter office that issued the document, by the two-fetter code (WIPO Standard ST3.) 3 For Japones patient documents, the indication of the year of the region of the Empirer may precede the sealing number of the patient document. 4 Kind of document when the patient document will be patient to the patient to the patient document will be patient to the patien

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

	Approved for use through 07/31/2012.
Application Number	10/556,069
Confirmation Number	6079
Filing Date	August 24, 2006
First Named Inventor	Peter MAYRHOFER
Art Unit	1633
Examiner Name	Sumesh KAUSHAL
Attorney Docket Number	Q90909

CERTIFICATION STATEMENT

Dlagea caa 1	37 CER	1 07 and	1 08 to make	the appropriat	e colection(c)

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.76(v)2).

That each item of information contained in the Information Disclosure Statement filed concurrently herewith was first cited in any communication from a foreign patent office in a counterpart foreign application, and that the communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of said Information Disclosure Statement. See 37 C.F.R. 1.704(d).

- ☑ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.
- □ None

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Tu A. Phan/	Date (YYYY-MM-DD)	2011-10-11
Name/Print	Tu A. Phan, Ph.D.	Registration Number	59,392

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or NPEP 901.04. 2 Enter office that issued the document, by the two-better code (NPPO Standard STS.3), 3 For Japanese patent document, the indication of the year of the reging of the Emperor may preced the sealing number of the patent document. 4 Kind of document, 4 Kind of document with the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.